Abzyme Biolabs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 12 Year, 10 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 1.00 M
- Revenue Growth -8.50%
- Profit Growth 54.22%
- Ebitda 90.28%
- Net Worth
- Total Assets 80.95%
About Abzyme Biolabs
Abzyme Biolabs Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 March 2012 and has a history of 12 years and ten months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.00 M.
Prasanna Narayanappa and Makarahalli Shoba serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24301KA2012PTC063066
- Company No.
063066
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Mar 2012
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Abzyme Biolabs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prasanna Narayanappa  | Director | 11-Mar-2013 | Current |
| Makarahalli Shoba | Director | 03-Jul-2015 | Current |
Financial Performance of Abzyme Biolabs.
Abzyme Biolabs Private Limited, for the financial year ended 2017, experienced Minor drop in revenue, with a 8.5% decrease. The company also saw a substantial improvement in profitability, with a 54.22% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abzyme Biolabs?
In 2017, Abzyme Biolabs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Taurus Lab Private LimitedPrasanna Narayanappa and Makarahalli Shoba are mutual person
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Apr 2019 | Others | ₹1.00 M | Open |
How Many Employees Work at Abzyme Biolabs?
Unlock and access historical data on people associated with Abzyme Biolabs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abzyme Biolabs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abzyme Biolabs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
